Search

Your search keyword '"Szondy, Klara"' showing total 8 results
Start Over Author "Szondy, Klara"
8 results on '"Szondy, Klara"'

1. Large-Scale Plasma Proteome Epitome Profiling is an Efficient Tool for the Discovery of Cancer Biomarkers

Author

Lazar, Jozsef, Antal-Szalmas, Peter, Kurucz, Istvan, Ferenczi, Annamaria, Jozsi, Mihaly, Tornyi, Ilona, Muller, Monika, Fekete, Janos Tibor, Lamont, John, FitzGerald, Peter, Gall-Debreceni, Anna, Kadas, Janos, Vida, Andras, Tardieu, Nadege, Kieffer, Yann, Jullien, Anne, Guergova-Kuras, Mariana, Hempel, William, Kovacs, Andras, Kardos, Tamas, Bittner, Nora, Csanky, Eszter, Szilasi, Maria, Losonczy, Gyorgy, Szondy, Klara, Galffy, Gabriella, Csada, Edit, Szalontai, Klara, Somfay, Attila, Malka, David, Cottu, Paul, Bogos, Krisztina, and Takacs, Laszlo

Published
2023
Full Text
View/download PDF

2. Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy.

Author

Hanna, Nasser, Shepherd, Frances A., Fossella, Frank V., Pereira, Jose R., De Marinis, Filippo, von Pawel, Joachim, Gatzemeier, Ulrich, Tsao, Thomas Chang Yao, Pless, Miklos, Muller, Thomas, Lim, Hong-Liang, Desch, Christopher, Szondy, Klara, Gervais, Radj, Shaharyar, Manegold, Christian, Paul, Sofia, Paoletti, Paolo, Einhorn, Lawrence, and Bunn Jr., Paul A.

Published
2023
Full Text
View/download PDF

3. Epidermal Growth Factor Receptor (EGFR) High Gene Copy Number and Activating Mutations in Lung Adenocarcinomas Are Not Consistently Accompanied by Positivity for EGFR Protein by Standard Immunohistochemistry

Author

Pinter, Ferenc, Papay, Judit, Almasi, Andrea, Sapi, Zoltan, Szabo, Edit, Kanya, Melinda, Tamasi, Anna, Jori, Balazs, Varkondi, Edit, Moldvay, Judit, Szondy, Klara, Keri, Gyorgy, Dominici, Massimo, Conte, Pierfranco, Eckhardt, Sandor, Kopper, Laszlo, Schwab, Richard, and Petak, Istvan

Published
2008
Full Text
View/download PDF

4. Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy

Author

Hanna, Nasser, Shepherd, Frances A., Fossella, Frank V., Pereira, Jose R., De Marinis, Filippo, von Pawel, Joachim, Gatzemeier, Ulrich, Chang Yao Tsao, Thomas, Pless, Miklos, Muller, Thomas, Lim, Hong-Liang, Desch, Christopher, Szondy, Klara, Gervais, Radj, Christian Manegold, Shaharyar, Paul, Sofia, Paoletti, Paolo, Einhorn, Lawrence, and Bunn, Paul A., Jr

Published
2004
Full Text
View/download PDF

6. Tumor Cell Expression of Heat Shock Protein (HSP) 72 is Influenced by HSP72 [HSPA1B A(1267)G] Polymorphism and Predicts Survival in Small Cell Lung Cancer (SCLC) Patients

Author

Szondy, Klara, primary, Rusai, Krisztina, additional, Szabó, Attila J., additional, Nagy, Andrea, additional, Gal, Krisztina, additional, Fekete, Andrea, additional, Kovats, Zsuzsanna, additional, Losonczy, Gyorgy, additional, Lukacsovits, József, additional, and Müller, Veronika, additional

Published
2012
Full Text
View/download PDF

8. Inhibition of EGFR tyrosine-kinase in NSCLC treatment: the Hungarian experience with gefitinib in the context of an expanded access programme.

Author

Ostoros G, Harisi R, Kovacs G, Horti J, Geczi L, Szondy K, Orosz M, Ferenczi E, Ruby E, and Dome B

Subjects
Adult, Aged, Antineoplastic Agents therapeutic use, Female, Gefitinib, Humans, Male, Middle Aged, Protein Kinase Inhibitors therapeutic use, Survival Rate, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung enzymology, ErbB Receptors antagonists & inhibitors, Lung Neoplasms drug therapy, Lung Neoplasms enzymology, Quinazolines therapeutic use
Abstract

The ZD1839 (Iressa, gefitinib) treatment in phase I trials for patients with advanced non-small cell lung cancer (NSCLC) was associated with disease stabilization and tumor regression. The aim of this study was to analyze the efficacy of gefitinib monotherapy as a second- or third-line treatment for locally-advanced and advanced NSCLC. Data for 50 patients were analyzed. Patients were treated at 5 centers in Hungary as part of the gefitinib Expanded Access Programme (EAP). The response rate was 10% (all partial responses), with disease stabilization in 46% of patients. Disease progression was observed in 44% of patients. The median survival according to the Kaplan-Meier method was 8 months. Median survival of patients with adenocarcinoma was significantly increased compared with squamous cell carcinoma and, of the patients responding to therapy, 80% had adenocarcinoma. The 1-year survival rate was 34%. All patients were evaluable for safety; the adverse events seen with gefitinib were generally mild and only two patients had to be withdrawn from the study due to adverse events. The Hungarian experience suggests gefitinib therapy is effective and well tolerated.

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results